Skip to content

Revenue at other companies

HTF
Heartflow, Inc. Common StockHTFL
$52.59M+41.3%
Cal-Maine Foods logo
Cal-Maine FoodsCALM
$666.95M-53.0%
DJT
Trump Media & Technology GroupDJT
$871.2K+6.1%
ADMA Biologics logo
ADMA BiologicsADMA
$114.49M-0.3%
Minerals Technologies logo
Minerals TechnologiesMTX
$546.9M+11.2%
Photronics logo
PhotronicsPLAB
$209.94M-0.5%

Other financials

Income statement

See full
Revenue$15.0K-97.8%
Operating income-$84.4M-34.6%
Net income-$78.7M-46.3%
EPS (diluted)-$1.18-45.7%

Balance sheet

See full
Cash & equivalents$35.7M+109%
Total debt$1.9M-44.3%
Total equity$456.2M-35.1%
Total assets$511.3M-30.9%

Cash flow

See full
Operating cash flow-$65.6M-20.6%
CapEx$1.6M+518%
Free cash flow-$67.2M-23.0%

Valuation

See full
Market cap$2.59B+75.2%
Enterprise value$2.55B+74.4%
P/S2,989.2×+2,794×

Profitability

See full
Operating margin-35,688.5%-39,114pp
Net margin-32,753.6%-35,519pp
FCF margin-26,125.8%-28,907pp

Returns & leverage

See full
Return on equity-48.9%-498pp
Debt / equity0.0×
Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celldex Therapeutics's revenue?
Celldex Therapeutics (CLDX) reported revenue of $15K in Q1 2026.
How has Celldex Therapeutics's revenue changed year-over-year?
Celldex Therapeutics's revenue decreased by 97.8% year-over-year, from $695K to $15K.
What is the long-term trend for Celldex Therapeutics's revenue?
Over 4 years (2021 to 2025), Celldex Therapeutics's revenue has grown at a -24.1% compound annual growth rate (CAGR), from $4.65M to $1.55M.